John Hartley

基本信息

Career Trajectory

Bio

He has published extensively in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics.
He is a Fellow of both the Royal Societies of Biology and Chemistry, an Honorary Member of the Royal College of Radiologists and a Fellow of the Academy of Pharmaceutical Sciences. He has also been Chair of the Protocol Safety and Review Board of Cancer Research UK Centre for Drug Development since 2000.

Research Interests

Papers共 138 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Figure S5.A from the MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Francesca Vena,Eleonora Li Causi,Manuel Rodriguez-Justo,Samantha Goodstal,Thorsten Hagemann,John A. Hartley,Daniel Hochhauser

crossref（2023）

Cited0Views0Bibtex

What’s New in the Use of Antibody-Drug Conjugates (adcs) Delivering Pyrrolobenzodiazepine (PBD) DNA Cross-Linkers for Cancer Therapy

John A Hartley

Expert opinion on biological therapy（2023）

Cited48Views0WOSBibtex

Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael Flynn,Francesca Zammarchi,Peter Tyrer,Ayse U. Akarca,Narinder Janghra,Charles E. Britten,Carin E.G. Havenith,Jean-Noel Levy,Arnaud Tiberghien,Luke A. Masterson,Conor Barry,François D’Hooge,Teresa Marafioti, Paul W.H.I. Parren, D G Williams,Philip W. Howard,Patrick H. van Berkel,John A. Hartley

openalex（2023）

Cited0Views0Bibtex

Supplementary Data from SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity

John A. Hartley,Anzu Hamaguchi,Marissa Coffils,Christopher R.H. Martin,Marie Suggitt,Zhizhi Chen,Stephen J. Gregson,Luke A. Masterson,Arnaud C. Tiberghien,Janet M. Hartley,Christopher Pepper, Thet,Christopher Fegan,David E. Thurston,Philip W. Howard

crossref（2023）

Cited0Views0Bibtex

Supplementary Methods, Figures 1 - 4, Table 1 from Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage

Gianmaria Liccardi,John A. Hartley,Daniel Hochhauser

openalex（2023）

Cited0Views0Bibtex

Figure S2.A from the MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Francesca Vena,Eleonora Li Causi,Manuel Rodriguez-Justo,Samantha Goodstal,Thorsten Hagemann,John A. Hartley,Daniel Hochhauser

openalex（2023）

Cited0Views0Bibtex

Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael Flynn,Francesca Zammarchi,Peter Tyrer,Ayse U. Akarca,Narinder Janghra,Charles E. Britten,Carin E.G. Havenith,Jean-Noel Levy,Arnaud Tiberghien,Luke A. Masterson,Conor Barry,François D’Hooge,Teresa Marafioti, Paul W.H.I. Parren, David G. Williams,Philip W. Howard,Patrick H. van Berkel,John Hartley

openalex（2023）

Cited0Views0Bibtex

Figure S4 from the MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Francesca Vena,Eleonora Li Causi,Manuel Rodriguez-Justo,Samantha Goodstal,Thorsten Hagemann,John A. Hartley,Daniel Hochhauser

crossref（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 138 篇Author StatisticsCo-AuthorSimilar Experts